Introduction {#s1}
============

It is estimated that about 12.7 million multiple cancer cases and 7.6 million cancer deaths have occurred in 2008 worldwide, with more than half of the cases and about two-thirds of the deaths in the developing countries [@pone.0094039-Jemal1]. The evidence is mounting that cancer is a complex disease results from interactions between multiple genetic backgrounds and environmental factors [@pone.0094039-Liu1], [@pone.0094039-Reeves1]. Of late, a number of studies demonstrate that genetic variants of the genes that regulate the activation and proliferation of T lymphocytes and nature killer (NK) cells may influence cancer risk [@pone.0094039-Zhang1], [@pone.0094039-Welsh1]. In the last decade, single nucleotide polymorphisms (SNPs) have been extensively investigated, and many studies have examined the hypothesis that genetic variants of the immune genes may be relevant to the risk of a variety of cancers [@pone.0094039-Sun1], [@pone.0094039-Hu1].

Cytotoxic T-lymphocyte antigen 4 (CTLA-4), also named CD152, is a member of the immunoglobulin superfamily. CTLA-4 is expressed mainly on activated T cells, acts as a vital restraining regulator of T-cell proliferation and activation, and induces Fas-independent apoptosis of activated T cells to further inhibit immune function of T-cell [@pone.0094039-Sun1], [@pone.0094039-Scheipers1]. Blocking CTLA-4 function and enhancing T cell activation, several different types of malignant neoplasms in tumor-transplanted mice were inhibited or cured, and owned long-lasting antitumor immunity [@pone.0094039-Vandenborre1]. It suggests that CTLA-4 plays an important role in carcinogenesis. *CTLA-4* gene is located on chromosome 2q33, and is composed of four exons that encode several functional domains of the CTLA-4 protein and possess several vital SNPs, such as the +49A/G (rs231775), -318C/T (rs5742909), CT60G/A (rs3087243), -1661A/G (rs4553808), and -1722T/C (rs733618) SNPs, etc [@pone.0094039-Sun1], [@pone.0094039-Ueda1].

A meta-analysis showed that *CTLA-4* +49A/G polymorphism may be a risk factor for cancer, whereas -318C/T and +6230G/A (CT60) polymorphisms were lack of association with cancer [@pone.0094039-Zhang1]. Of late, Geng and colleagues reported a meta-analysis with a negative result on the association between *CTLA-4* -1722T/C polymorphism and cancer risk [@pone.0094039-Geng1]. Linkage disequilibrium (LD) plot of *CTLA-4* (involving rs733618, rs4553808, rs5742909, rs231775 and rs3087243) was generated using Haploview 4.2 program and the results suggest that −1661A/G (rs4553808) and −318C/T (rs5742909) are in high LD; the others are in low LD [@pone.0094039-Geng1]. The *CTLA-4* -1722T/C polymorphism has not been investigated in esophageal cancer. To further investigate this potential relationship, we decided to evaluate the association of *CTLA-4* -1722T/C polymorphism with esophageal cancer risk in a hospital based case-control study, and then performed a comprehensive meta-analysis to derive a more precise result.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

This hospital-based case--control study included 629 sporadic esophageal squamous cell carcinoma (ESCC) cases and 686 cancer-free subjects consecutively recruiting from the Affiliated People\'s Hospital of Jiangsu University and Affiliated Hospital of Jiangsu University (Zhenjiang City, Jiangsu Province, China), between October 2008 and December 2010. All recruited subjects were local residents of Han Chinese population, and all ESCC subjects were diagnosed by surgical resection and pathologic examination. The ESCC subjects who had a history of personal malignant tumor or autoimmune disorder, or had undergone radiotherapy or chemotherapy were excluded. Ethnicity, gender and average age (±5 years) of the controls were well matched to esophageal cancer cases. The control individuals were selected from the two hospitals for cure of fracture. At recruitment, this hospital based case-control study was approved by the Ethics Committee of Jiangsu University (Zhenjiang, China). Information of all subjects was collected from a structured questionnaire which was administered by two experienced research doctors. The information of demographic data (e.g. age, gender) and related risk factors (such as, tobacco use and alcohol consumption) is listed in [**Table 1**](#pone-0094039-t001){ref-type="table"}. Each subject signed the written informed consent and donated 2-ml sample of peripheral blood.

10.1371/journal.pone.0094039.t001

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls.

![](pone.0094039.t001){#pone-0094039-t001-1}

  Variable                     Cases (n = 629)   Controls (n = 686)           *P* [a](#nt101){ref-type="table-fn"}  
  --------------------------- ----------------- -------------------- ------- -------------------------------------- -------------
  **Age (years)** mean ± SD     62.85 (±8.13)      62.58 (±7.89)      0.541                                         
  **Age (years)**                                                                                                       0.155
  \<63                               310               49.28           365                   53.21                  
  ≥63                                319               50.72           321                   46.79                  
  **Sex**                                                                                                               0.185
  Male                               444               70.59           461                   67.20                  
  Female                             185               29.41           225                   32.80                  
  **Tobacco use**                                                                                                    **\<0.001**
  Never                              355               56.44           499                   72.74                  
  Ever                               274               43.56           187                   27.26                  
  **Alcohol use**                                                                                                    **\<0.001**
  Never                              428               68.04           526                   76.68                  
  Ever                               201               31.96           160                   23.32                  

Two-sided *χ* ^2^ test and student *t* test; Bold values are statistically significant (*P*\<0.05).

DNA extraction, SNP selection, and genotyping {#s2b}
---------------------------------------------

Blood samples were collected with ethylenediamine tetra-acetic acid (EDTA) anticoagulant vacutainer tubes (BD Franklin Lakes NJ, USA). Genomic DNA was extracted from lymphocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Berlin, Germany) and DNA samples were frozen at −80°C. Genotyping of *CTLA-4* -1722T/C polymorphism was carried out using the polymerase chain reaction-ligase detection reactions (PCR-LDR) method [@pone.0094039-Chen1]. The Shanghai Biowing Applied Biotechnology Company provides technical support for genotyping. One hundred and sixty samples were randomly selected and reciprocally tested with directly sequencing for quality control, and the reproducibility were 100%. The primers of directly sequencing used for *CTLA-4* -1722T/C genotyping were as follows: F: 5\' GCAATAACAACCTAATGGGCAC 3\'; **R**: 5\' ACTTCCACAGGCTGAACCACT 3\' (**[Figure S1](#pone.0094039.s001){ref-type="supplementary-material"}**).

Statistical analysis {#s2c}
--------------------

Chi-square test (*χ* ^2^) was conducted to measure the differences in the distributions of genotypes, demographic characteristics and selected variables between esophageal cancer cases and controls. Genotype frequencies of *CTLA-4* -1722T/C polymorphism among the controls were tested for Hardy--Weinberg equilibrium (HWE) using an internet-based calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The associations between *CTLA-4* -1722T/C locus and the risk of ESCC were analyzed by unconditional logistic regression for crude ORs and adjusted ORs when it was appropriate. Statistical analyses were implemented in SAS 9.1.3 software (SAS Institute, Cary, NC). A *P*\<0.05 (two-tailed) was defined as the criterion of statistical significance.

Meta analysis {#s2d}
-------------

The meta-analysis is reported on the basis of the Preferred Reporting Items for Meta-analyses (PRISMA) guideline (**[Checklist S1](#pone.0094039.s002){ref-type="supplementary-material"}**) [@pone.0094039-Moher1].

Embase, PubMed, and CBM (Chinese BioMedical Disc), as well as CNKI (China National Knowledge Infrastructure) database were searched up to August 1st, 2013 for publications investigating the association of *CTLA-4* -1722T/C polymorphism with cancer risk. The combination terms were 'cancer' or 'tumor' or 'carcinoma' or 'neoplasm' and 'cytotoxic T-lymphocyte antigen 4′ or '*CTLA-4*′ or 'CD152', annexed with 'mutation' or 'variant' or 'SNP' or 'polymorphism'. In addition, the publication language was restricted to English and Chinese, and all studies performed in human subjects were identified. The search results were supplemented by checking all references listed in these studies and published reviews. Included studies were qualified if they met the major included criteria: (1) designed as a retrospective or nested case-control study, (2) evaluated the *CTLA-4* -1722T/C polymorphism and cancer risk, (3) provide genotype counts of *CTLA-4* -1722T/C polymorphism between cancer cases and controls, and (4) control genotype distributions consistent with HWE. The major excluded criteria were: (1) not case-control studies, (2) review publications and (3) overlapping data. Information was carefully and independently extracted by three reviewers (W. Tang, H. Qiu, and H. Jiang). In case of conflicting evaluations, differences were resolved by further discussion among all authors. The following data was extracted: first author, year of publication, cancer type, country, ethnicity, number of cases and controls, genotype method, allele and genotype frequency, and HWE in controls.

In this meta-analysis, the crude odds ratio (OR) with the corresponding 95% confidence intervals (95% CI) was used to assess the strength of association between the *CTLA-4* -1722T/C polymorphism and cancer risk. The Z-test and *P*-value (two-tailed) was used to measure the significance of the pooled OR, and statistical significance was defined as *P*\<0.05 (two-tailed). Heterogeneity among studies was evaluated by a Chi-square-based I^2^ test, I^2^\<25% indicated low heterogeneity, 25%≤I^2^≤50% indicated moderate heterogeneity, and I^2^\>50% indicated large heterogeneity [@pone.0094039-Higgins1]. If I^2^\>50% or *P*\<0.10, the pooled ORs were calculated by the random-effects model (the DerSimonian--Laird method), otherwise the fixed-effects model was implemented (the Mantel--Haenszel method). Subgroup analyses were implemented to measure ethnicity-specific, cancer type-specific and system-specific effects according to ethnicity, cancer type (if any cancer type evaluated by less than three individual investigations, it was combined into \"other cancers\") and system. The funnel plot and Egger\'s test were carried out to measure publication bias, which was evaluated by visual inspection of an asymmetric plot. For heterogeneity, funnel plot and Egger\'s test, statistical significance was considered at *P*\<0.1. In this meta-analysis, all statistical analyses were conducted by STATA software (version 12.0).

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

The demographics and risk factors of all subjects are presented in [**Table 1**](#pone-0094039-t001){ref-type="table"}. The results indicated that cases and controls were fully matched by age and gender. However, there was significant difference on drinking status and smoking between patients and controls (*P*\<0.001). The primary information of *CTLA-4* -1722T/C polymorphism was showed in [**Table 2**](#pone-0094039-t002){ref-type="table"}. For this SNP, the genotyping success rate was 96.43% in all samples. Minor allele frequency (MAF) of controls in our study, was similar to the database of Chinese for this SNP ([**Table 2**](#pone-0094039-t002){ref-type="table"}). The genotypic frequencies for *CTLA-4* -1722T/C polymorphism among controls were used to evaluated deviation from the HWE, and the result was in HWE (*P* = 0.284) ([**Table 2**](#pone-0094039-t002){ref-type="table"}).

10.1371/journal.pone.0094039.t002

###### Primary information for *CTLA4* -1722T/C (rs733618) polymorphism.
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  Genotyped SNPs                                                            *CTLA4* -1722T/C (rs733618)
  ------------------------------------------------------------------------ -----------------------------
  Chromosome                                                                             2
  Function                                                                          nearGene-5
  Chr Pos (Genome Build 36.3)                                                        204439189
  Regulome DB Score[a](#nt102){ref-type="table-fn"}                                   No Data
  TFBS[b](#nt103){ref-type="table-fn"}                                                   Y
  Splicing (ESE or ESS)                                                                 ---
  miRNA (miRanda)                                                                       ---
  nsSNP                                                                                 ---
  MAF[c](#nt104){ref-type="table-fn"} for Chinese in database                          0.390
  MAF in our controls (n = 686)                                                        0.414
  *P* value for HWE[d](#nt105){ref-type="table-fn"} test in our controls               0.701
  Genotyping method[e](#nt106){ref-type="table-fn"}                                     LDR
  \% Genotyping value                                                                 96.43%

http://[www.regulomedb.org/](http://www.regulomedb.org/);

TFBS: Transcription Factor Binding Site (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>);

MAF: minor allele frequency;

HWE: Hardy--Weinberg equilibrium;

LDR: Ligation Detection Reaction.

Single-locus analysis {#s3b}
---------------------

In the single locus analyses, the genotype frequencies of *CTLA-4* -1722T/C were 16.53% (CC), 49.10% (TC) and 34.37% (TT) in the patients, and 17.50% (CC), 47.79% (TC) and 34.70% (TT) in the controls, and the difference was no statistically significant (*P* = 0.862) ([**Table 3**](#pone-0094039-t003){ref-type="table"}). In this case-control study, logistic regression analyses showed that the *CTLA-4* -1722T/C SNP was not associated with the risk of ESCC. Tobacco use and alcohol consumption are two strong environmental factors, we examined the association in a stratified analysis by these two factors and the results were null association ([**Table 4**](#pone-0094039-t004){ref-type="table"}).

10.1371/journal.pone.0094039.t003

###### Logistic regression analyses of associations between *CTLA4* -1722T/C (rs733618) polymorphisms and risk of ESCC.
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  Genotype               Cases (n = 629)   Controls (n = 686)   Crude OR (95%CI)    *P*    Adjusted OR [a](#nt107){ref-type="table-fn"} (95%CI)    *P*                       
  --------------------- ----------------- -------------------- ------------------ ------- ------------------------------------------------------ ------- ------------------- -------
  *CTLA4* rs733618T/C                                                                                                                                                        
  TT                           210               34.37                228          34.70                           1.00                                         1.00         
  TC                           300               49.10                314          47.79                    1.04 (0.81--1.33)                     0.770   1.06 (0.83--1.37)   0.625
  CC                           101               16.53                115          17.50                    0.95 (0.69--1.32)                     0.776   0.97 (0.69--1.35)   0.846
  CC vs. TC vs. TT                                                                                                                                0.862                      
  TC+CC                        401               65.63                429          65.30                    1.02 (0.81--1.28)                     0.901   1.04 (0.82--1.32)   0.755
  TT+TC                        510               83.47                542          82.50                           1.00                                         1.00         
  CC                           101               16.53                115          17.50                    0.93 (0.70--1.25)                     0.645   0.93 (0.69--1.26)   0.649
  T allele                     720               58.92                770          58.60                    0.99 (0.84--1.16)                     0.870                      
  C allele                     502               41.08                544          41.40                                                                                     

Adjusted for age, sex, smoking and drinking status; Bold values are statistically significant (*P*\<0.05).

10.1371/journal.pone.0094039.t004

###### Stratified analyses between *CTLA4* -1722T/C (rs733618) polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption.
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  Variable               *CTLA4* rs733618 T/C (case/control)[a](#nt108){ref-type="table-fn"}   Adjusted OR[b](#nt109){ref-type="table-fn"} (95% CI); *P*                                                                                                                           
  --------------------- --------------------------------------------------------------------- ----------------------------------------------------------- ------- --------- ------ ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                                                                                              
  Male                                                 150/154                                                          209/214                            70/76   279/290   1.00   1.04 (0.77--1.40); *P*: 0.815   0.96 (0.64--1.43); *P*: 0.828   1.02 (0.76--1.35); *P*: 0.916   0.94 (0.65--1.35); *P*: 0.723
  Female                                                60/74                                                           91/100                             31/39   122/139   1.00   1.10 (0.70--1.72); *P*: 0.676   1.02 (0.57--1.83); *P*: 0.955   1.08 (0.71--1.64); *P*: 0.731   0.96 (0.57--1.63); *P*: 0.888
  Age                                                                                                                                                                                                                                                                              
  \<63                                                 102/125                                                          139/162                            60/60   199/222   1.00   1.05 (0.74--1.51); *P*: 0.773   1.24 (0.79--1.96); *P*: 0.353   1.11 (0.79--1.55); *P*: 0.559   1.21 (0.80--1.82); *P*: 0.371
  ≥63                                                  108/103                                                          161/152                            41/55   202/207   1.00   1.05 (0.73--1.49); *P*: 0.807   0.73 (0.45--1.20); *P*: 0.214   0.96 (0.69--1.35); *P*: 0.820   0.71 (0.46--1.11); *P*: 0.136
  Smoking status                                                                                                                                                                                                                                                                   
  Never                                                108/171                                                          185/218                            54/85   239/303   1.00   1.31 (0.96--1.80); *P*: 0.092   0.99 (0.65--1.52); *P*: 0.963   1.22 (0.91--1.65); *P*: 0.190   0.84 (0.58--1.24); *P*: 0.380
  Ever                                                 102/57                                                           115/96                             47/30   162/126   1.00   0.71 (0.46--1.10); *P*: 0.123   0.91 (0.51--1.62); *P*: 0.749   0.76 (0.50--1.14); *P*: 0.187   1.11 (0.66--1.86); *P*: 0.693
  Alcohol consumption                                                                                                                                                                                                                                                              
  Never                                                145/178                                                          208/231                            63/91   271/322   1.00   1.17 (0.87--1.58); *P*: 0.300   0.89 (0.59--1.33); *P*: 0.563   1.09 (0.82--1.45); *P*: 0.548   0.81 (0.56--1.17); *P*: 0.257
  Ever                                                  65/50                                                            92/83                             38/24   130/107   1.00   0.81 (0.50--1.32); *P*: 0.399   1.20 (0.63--2.29); *P*: 0.577   0.90 (0.57--1.42); *P*: 0.648   1.36 (0.76--2.43); *P*: 0.296

The genotyping was successful in 611 (97.1%) ESCC cases, and 657 (95.8%) controls for *CTLA4* -1722T/C (rs733618);

Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

Eligible articles for meta-analysis {#s3c}
-----------------------------------

The initial search yielded a total of 345 potentially relevant publications. After applying additional filters, 12 case-control studies in 11 publications and our study were eligible for inclusion. The detailed process of selecting and excluding articles is presented in [**Figure 1**](#pone-0094039-g001){ref-type="fig"}.

![Flow diagram of articles selection process for *CTLA-4* -1722T/C (rs733618) polymorphism and cancer risk meta-analysis.](pone.0094039.g001){#pone-0094039-g001}

Study characteristics {#s3d}
---------------------

There were two groups in an article conducted by Hadinia et al. [@pone.0094039-Hadinia1], we treated them separately. In total 12 separate studies plus our case-control study involving a total of 3420 cancer cases and 3675 controls were included in this meta-analysis. Among the 13 case-control studies, three investigated breast cancer [@pone.0094039-Erfani1]--[@pone.0094039-Li2], three investigated gastric cancer [@pone.0094039-Hadinia1], [@pone.0094039-QiYQ1], [@pone.0094039-SongJQ1], and the other studies investigated cervical cancer, lung cancer, esophageal cancer, colorectal cancer, and oral cancer [@pone.0094039-Sun1], [@pone.0094039-Hadinia1], [@pone.0094039-Jiang1]--[@pone.0094039-Bharti1]. As for subjects in these studies, 8 were Asians [@pone.0094039-Sun1], [@pone.0094039-Li1]--[@pone.0094039-Jiang1], [@pone.0094039-Bharti1] and 5 were Caucasians[@pone.0094039-Hadinia1], [@pone.0094039-Erfani1] [@pone.0094039-Khaghanzadeh1], [@pone.0094039-Rahimifar1]. Characteristics of each included study are presented in [**Table 5**](#pone-0094039-t005){ref-type="table"}. The detailed distribution of the *CTLA-4* -1722T/C polymorphism and allele among cases and controls is presented in [**Table 6**](#pone-0094039-t006){ref-type="table"}.

10.1371/journal.pone.0094039.t005

###### Characteristics of populations and cancer types of the individual studies included in the meta-analysis.
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  study                  year   country   ethnicity       cancer type      No. of cases/controls      Genotype Method
  --------------------- ------ --------- ------------ ------------------- ----------------------- ------------------------
  Bharti et al.          2013    India      Asians        oral cancer             130/180                 PCR-RFLP
  Li et al.              2012    China      Asians       breast cancer            581/566                 PCR-RFLP
  Qi et al.              2012    China      Asians      gastric cancer            118/96                  PCR-RFLP
  Jiang et al.           2011    China      Asians      cervical cancer           100/100               MALDI-TOF-MS
  Khaghanzadeh et al.    2010    Iran     Caucasians      lung cancer             127/124            PCR-RFLP, PCR-ARMS
  Rahimifar et al.       2010    Iran     Caucasians    cervical cancer           55/110             PCR-RFLP, PCR-ARMS
  Li et al.              2008    China      Asians       breast cancer            328/327                 PCR-RFLP
  Sun et al.             2008    China      Asians        lung cancer             765/800          PCR-RFLP, MALDI-TOF MS
  Hadinia et al.         2007    Iran     Caucasians    gastric cancer            46/190               RFLP, PCR-ARMS
  Hadinia et al.         2007    Iran     Caucasians   colorectal cancer          109/190              RFLP, PCR-ARMS
  Song et al.            2006    China      Asians      gastric cancer            183/116                 PCR-RFLP
  Erfani et al.          2006    Iran     Caucasians     breast cancer            283/245                 PCR-CTPP
  Our study              2013    China      Asians     esophageal cancer          629/686                 PCR-LDR

MALDI--TOF--MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry.

PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism.

PCR-LDR: polymerase chain reaction-ligase detection reaction.

PCR-ARMS: AmplificationRefractory Mutation System-Polymerase Chain Reaction.

10.1371/journal.pone.0094039.t006

###### Distribution of *CTLA-4* -1722T/C (rs733618 T/C) polymorphisms genotype and allele among multiple cancer patients and controls.
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                                       case   control   case   control   HWE,*P* value                                  
  ---------------------------- ------ ------ --------- ------ --------- --------------- ----- ----- ------ ----- ------ ----------
  Qi et al.                     2012    40      69       9       37           45         14    87    149    73    119    0.957723
  Li et al.                     2012   184      276     114      207          256        88    504   644    432   670    0.552314
  Jiang et al.                  2011    37      49       14      43           39         18    77    123    75    125    0.092957
  Rahimifar et al.              2010    46       8       1       90           20          0    10    100    20    200    0.294266
  Khaghanzadeh et al.           2010   106      19       1       98           16          1    21    231    18    212    0.702320
  Sun et al.                    2008   719      43       3       762          37          1    49    1481   39    1561   0.435355
  Li et al.                     2008   125      163      40      111          168        48    243   413    264   390    0.224758
  Hadinia et al.(colorectal)    2007    97      12       0       165          24          0    12    206    24    354    0.351131
  Hadinia et al.(gastric)       2007    42       4       0       165          24          0     4     88    24    354    0.351131
  Erfani et al.                 2006   225      54       3       204          41          0    60    504    41    449    0.152921
  Bharti et al.                 2013    92      25       6       131          46          3    37    209    52    308    0.648604
  Song et al.                   2006    62      113      8       45           54         17    129   237    88    144    0.902590
  Our study                     2013   210      300     101      228          314        115   502   720    544   770    0.700586

HWE: Hardy--Weinberg equilibrium.

Meta-analysis results {#s3e}
---------------------

After combining all qualified studies, a total of 3420 cancer cases and 3675 controls from 13 eligible case--control studies were included for meta-analysis of the association between the CTLA-4 -1722T/C polymorphism and cancer risk. There was null association of *CTLA-4* -1722T/C polymorphism with overall cancer risk in all genetic models ([**Table 7**](#pone-0094039-t007){ref-type="table"} **,** [**Table 8**](#pone-0094039-t008){ref-type="table"} **,** [**Table 9**](#pone-0094039-t009){ref-type="table"} **,** [**Figure 2**](#pone-0094039-g002){ref-type="fig"} **, and** [**Figure 3**](#pone-0094039-g003){ref-type="fig"}). In a stratified analysis by ethnicity, the similar results were observed in both Asians and Caucasians ([**Table 7**](#pone-0094039-t007){ref-type="table"}). In a stratified analysis by cancer type, there was a decreased risk of gastric cancer in two genetic models: CC vs. TC+TT (OR, 0.36; 95% CI, 0.19--0.66; *P* = 0.001) and CC vs. TT (OR, 0.45; 95% CI, 0.23--0.86; *P* = 0.016) ([**Table 8**](#pone-0094039-t008){ref-type="table"}). In a stratified analysis by system, null association was also observed ([**Table 9**](#pone-0094039-t009){ref-type="table"}).

![Meta-analysis with a fixed-effects model for the association between the risk of cancer and the *CTLA-4* -1722T/C polymorphism (C vs. T).](pone.0094039.g002){#pone-0094039-g002}

![Meta-analysis with a random-effects model for the association between the risk of cancer and the *CTLA-4* -1722T/C polymorphism (CC vs. TC+TT).](pone.0094039.g003){#pone-0094039-g003}

10.1371/journal.pone.0094039.t007

###### Summary of results of the meta-analysis from different comparative genetic models in the subgroup analysis by ethnicity.
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  Polymorphism         Genetic comparison   Population       OR(95%CI); *P*        Test of heterogeneity  
  ------------------- -------------------- ------------ ------------------------- ----------------------- ---
                          CC+TC vs. TT         All       1.09(0.97--1.22);0.159         0.762,0.0%         F
                                              Asians     1.09(0.97--1.24);0.160         0.494,0.0%         F
                                            Caucasians   1.04(0.78--1.41);0.773         0.767,0.0%         F
                          CC vs. TC+TT         All       0.90(0.64--1.27);0.553         0.016,54.1%        R
                                              Asians     0.86(0.60--1.23);0.400         0.008,63.2%        R
                                            Caucasians   3.27(0.65--16.32);0.149        0.570,0.0%         F
  *CTLA-4* -1722T/C        CC vs. TT           All       0.98(0.70--1.37);0.906         0.050,45.3%        R
                                              Asians     0.94(0.66--1.33);0.719         0.028,55.4%        R
                                            Caucasians   3.29(0.66--16.46);0.146        0.575,0.0%         F
                           TC vs. TT           All       1.09(0.97--1.23);0.154         0.641,0.0%         F
                                              Asians     1.11(0.97--1.26);0.124         0.358,9.3%         F
                                            Caucasians   1.01(0.74--1.36);0.970         0.792,0.0%         F
                            C vs. T            All       1.04(0.95--1.13);0.383         0.577,0.0%         F
                                              Asians     1.03(0.95--1.13);0.460         0.301,16.4%        F
                                            Caucasians   1.08(0.82--1.43);0.575         0.744,0.0%         F

F indicates fixed model; R indicates random model.

10.1371/journal.pone.0094039.t008

###### Summary of results of the meta-analysis from different comparative genetic models in the subgroup analysis by cancer type.

![](pone.0094039.t008){#pone-0094039-t008-8}

  Polymorphism        Genetic comparison    Cancer type           OR(95%CI); *P*         Test of heterogeneity  
  ------------------ -------------------- ---------------- ---------------------------- ----------------------- ---
                         CC+TC vs. TT           All           1.09(0.97--1.22);0.159          0.762,0.0%         F
                                           Gastric cancer     1.15(0.81--1.62);0.430          0.571,0.0%         F
                                           Breast cancer      1.10(0.83--1.47);0.514          0.100,56.5%        R
                                           Other cancers      1.05(0.89--1.24);0.589          0.903,0.0%         F
                         CC vs. TC+TT           All           0.90(0.64--1.27);0.553          0.016,54.1%        R
                                           Gastric cancer   **0.36(0.19--0.66);0.001**        0.347,0.0%         F
                                           Breast cancer      1.10(0.68--1.77);0.689          0.121,52.7%        R
                                           Other cancers      0.98(0.76--1.28);0.903          0.374,6.6%         F
  *CTLA-4*-1722T/C        CC vs. TT             All           0.98(0.70--1.37);0.906          0.050,45.3%        R
                                           Gastric cancer   **0.45(0.23--0.86);0.016**        0.412,0.0%         F
                                           Breast cancer      1.15(0.60--2.22);0.672          0.046,67.6%        R
                                           Other cancers      1.04(0.78--1.39);0.798          0.496,0.0%         F
                          TC vs. TT             All           1.09(0.97--1.23);0.154          0.641,0.0%         F
                                           Gastric cancer     1.34(0.94--1.91);0.107          0.392,0.0%         F
                                           Breast cancer      1.09(0.90--1.31);0.383          0.259,25.9%        F
                                           Other cancers      1.04(0.88--1.24);0.637          0.741,0.0%         F
                           C vs. T              All           1.04(0.95--1.13);0.383          0.577,0.0%         F
                                           Gastric cancer     0.90(0.70--1.15);0.406          0.833,0.0%         F
                                           Breast cancer      1.09(0.85--1.41);0.504          0.044,68.0%        R
                                           Other cancers      1.02(0.90--1.16);0.733          0.931,0.0%         F

F indicates fixed model; R indicates random model.

10.1371/journal.pone.0094039.t009

###### Summary of results of the meta-analysis from different comparative genetic models in the subgroup analysis by system.
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  Polymorphism        Genetic comparison            Cancer type                 OR(95%CI); *P*        Test of heterogeneity  
  ------------------ -------------------- -------------------------------- ------------------------- ----------------------- ---
                         CC+TC vs. TT                   All                 1.09(0.97--1.22);0.159         0.762,0.0%         F
                                              Digestive system cancer       1.02(0.86--1.22);0.797         0.839,0.0%         F
                                           Reproductive and breast cancer   1.12(0.95--1.32);0.186         0.275,22.0%        F
                                             Respiratory system cancer      1.22(0.84--1.78);0.288         0.697,0.0%         F
                         CC vs. TC+TT                   All                 0.90(0.64--1.27);0.553         0.016,54.1%        R
                                              Digestive system cancer       0.71(0.33--1.53);0.381         0.008,74.5%        R
                                           Reproductive and breast cancer   1.11(0.88--1.40);0.395         0.171,37.5%        F
                                             Respiratory system cancer      1.99(0.37--10.85);0.425        0.498,0.0%         F
  *CTLA-4*-1722T/C        CC vs. TT                     All                 0.98(0.70--1.37);0.906         0.050,45.3%        R
                                              Digestive system cancer       0.79(0.41--1.52);0.476         0.056,60.3%        R
                                           Reproductive and breast cancer   1.18(0.91--1.53);0.217         0.111,46.7%        F
                                             Respiratory system cancer      2.02(0.37--10.99);0.417        0.499,0.0%         F
                          TC vs. TT                     All                 1.09(0.97--1.23);0.154         0.641,0.0%         F
                                              Digestive system cancer       1.06(0.88--1.27);0.529         0.386,4.8%         F
                                           Reproductive and breast cancer   1.10(0.92--1.31);0.289         0.392,2.6%         F
                                             Respiratory system cancer      1.19(0.81--1.75);0.367         0.791,0.0%         F
                           C vs. T                      All                 1.04(0.95--1.13);0.383         0.577,0.0%         F
                                              Digestive system cancer       0.96(0.85--1.09);0.569         0.966,0.0%         F
                                           Reproductive and breast cancer   1.09(0.96--1.23);0.168         0.175,37.0%        F
                                             Respiratory system cancer      1.24(0.87--1.78);0.232         0.595,0.0%         F

F indicates fixed model; R indicates random model.

Tests for publication bias, sensitivity analyses, and heterogeneity {#s3f}
-------------------------------------------------------------------

In this meta-analysis, potential publication bias was detected by Begg\'s Funnel plot and Egger\'s test ([**Figure 4**](#pone-0094039-g004){ref-type="fig"}), and the shape of funnel was symmetry in all genetic model. It suggested that there were no publication bias for overall cancer in this meta-analysis (C vs. T: Begg\'s test *P* = 0.855, Egger\'s test *P* = 0.675; CC vs. TT: Begg\'s test *P* = 0.350, Egger\'s test *P* = 0.709; TC vs. TT: Begg\'s test *P* = 0.583, Egger\'s test *P* = 0.702; CC+TC vs. TT: Begg\'s test *P* = 0.161, Egger\'s test *P* = 0.576; CC vs. TT+TC: Begg\'s test *P* = 0.533, Egger\'s test *P* = 0.845).

![Begg\'s funnel plot of meta-analysis of between the *CTLA-4* -1722T/C polymorphism and the risk of cancer (fixed--effects estimates) (C vs. T compare genetic model).](pone.0094039.g004){#pone-0094039-g004}

Sensitivity analyses were carried out to detect the influence of each individual dataset on the pooled OR, with each study dataset set dropped at a time. The outcomes did not change when any individual study was omitted, suggesting the stability of our results ([**Figure 5**](#pone-0094039-g005){ref-type="fig"}) (data not shown).

![Sensitivity analysis of the influence of C vs. T in overall cancer meta--analysis (fixed--effects estimates).](pone.0094039.g005){#pone-0094039-g005}

Large heterogeneities among the studies were indentified in the recessive model and homozygous model. Since tumor origin, ethnicity and system can influence the results from meta--analyses, we carried out subgroup analyses and the results were presented in [**Table 7**](#pone-0094039-t007){ref-type="table"} **,** [**Table 8**](#pone-0094039-t008){ref-type="table"} and [**Table 9**](#pone-0094039-t009){ref-type="table"}. The results indicated that breast cancer, digestive system cancer and Asian population subgroup may contribute to the major heterogeneity. As shown in [**Table 7**](#pone-0094039-t007){ref-type="table"}, heterogeneity was significant in the recessive model. Further analysis was conducted by Galbraith radial plot in the recessive model ([**Figure 6**](#pone-0094039-g006){ref-type="fig"}), and the result showed one outlier might contribute to the major sources of heterogeneity. From the forest plot in the recessive model ([**Figure 2**](#pone-0094039-g002){ref-type="fig"}), one can identify that a case-control study conducted by Erfani et al.[@pone.0094039-Erfani1] contributes the main heterogeneity.

![Galbraith radial plot of meta--analysis (CC vs. TC+TT compare genetic model).](pone.0094039.g006){#pone-0094039-g006}

Discussion {#s4}
==========

Of late, several studies have investigated the association between *CTLA-4* -1722T/C polymorphism and multiple cancers, a decisive answer is lacking. In this study, a case-control study in Han Chinese population, along with a meta-analysis on overall cancer, attempted to derive a comprehensive evaluation and the results were non-significance. To the best of our knowledge, this is the first case-control study investigating the association between *CTLA-4* -1722T/C polymorphism and esophageal cancer risk.

Cancer and autoimmune disease are both multifactorial disorders that results from complex interactions between genetic backgrounds and environmental factors. The *CTLA-4* -1722T/C polymorphism (T→C) would reduce a transcription factor binding site for nuclear factor 1 and weaken the expression of cell surface CTLA-4 [@pone.0094039-Geng1], [@pone.0094039-Jones1], which might play an important role in cancer and autoimmune disease susceptibility. Several meta-analyses showed that *CTLA-4* -1722T/C polymorphism might be a risk factor for systemic lupus erythematosus susceptibility [@pone.0094039-Zhu1]--[@pone.0094039-Zhai1]. However, the association between this locus and cancer risk was inconclusive. With a growing interest in the associations of genetic polymorphisms and cancer, several studies have examined the hypothesis that *CTLA-4* -1722T/C polymorphism is relevant to the risk of a number of cancers; however, the results remain elusive. Considering the fact that most common SNPs usually make low penetrance cancer susceptibility, this study includes 13 case-control studies with relatively large sample sizes to obtain a precise evaluation between *CTLA-4* -1722T/C genetic variation and cancer risk. One individual study has reported positive signal of *CTLA-4* -1722T/C polymorphism with cancer [@pone.0094039-Li2]; the other individual study has reported negative signal [@pone.0094039-SongJQ1]; however, as demonstrated in our overall genetic model results among 7098 subjects, there were non-significance, even in different population subgroups and different system. In a stratified analysis by cancer type, the protective effect conferred by the recessive model and homozygous model was appreciably obvious in gastric cancer subgroup. Considering only three case-control studies were conducted in gastric cancer subgroup and these studies were small sample sizes, which might restrict power to confirm a real influence or generate a fluctuated assessment. All results should be interpreted with very caution. It is also possible that the potential function of this polymorphism is diluted or covered by other genetic background or environment factors, and these important factors should not be ignored. Considering only 13 case-control studies were recruited in this meta-analysis and most of these studies were small sample sizes, in the future, further investigations with large sample sizes should be carried out to confirm or refute these results.

Some merit of current study should be adequate consideration. First, this is to date the first case-control study detecting the association of *CTLA-4* gene -1722T/C polymorphism with esophageal cancer. Second, the findings of our case-control study conform to that of the subsequent meta-analysis. Third, in our case-control study, control genotype distributions were consistent with HWE showed our results were less prone to selection bias, the shape of funnel plot indicated that there were no publication bias in current meta-analysis. Fourth, relatively low heterogeneity was observed between publications for *CTLA-4* -1722T/C polymorphism.

In addition, some limitations in current study should be acknowledged when interpreting our results. First, in this case-control study, all cases and controls were recruited from two hospitals and might not fully represent the general Chinese populations. Second, all included case--control studies for meta-analysis were from Asians and Caucasians; thus, our findings might only be suitable for these two populations. Third, only published studies were recruited in this meta-analysis, publication bias might have inevitably occurred. Fourth, due to the lack of uniform background data for recruited studies, data were not further stratified by other factors (such as, age, gender, smoking, alcohol consumption, and other lifestyle factors). Fifth, in this study, we focused on only -1722T/C polymorphism in *CTLA-4*, and did not consider other susceptibility genes or polymorphisms. For the low penetrance cancer susceptibility gene effects from SNP, these important genetic and environmental factors should be adequately considered.

In summary, this case-control study along with a meta-analysis, failed to confirm the association between *CTLA-4* -1722T/C polymorphism and cancer risk, even across different ethnic subgroups and different systems. In the future, further investigations with large sample sizes and detailed gene--environment data, should be carried out to confirm or refute these results.

Supporting Information {#s5}
======================

###### 

Direct sequencing analyses for genotypes of CTLA-4 -1722T/C SNP (The three charts represent three genotypes).

(TIF)
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Click here for additional data file.

###### 

PRISMA checklist, Checklist of items to include when reporting a systematic review or meta-analysis (diagnostic review consisting of cohort studies).

(DOCX)
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Click here for additional data file.
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